ADC Therapeutics (ADCT) Free Cash Flow (2023 - 2026)

ADC Therapeutics has disclosed Free Cash Flow across 4 years of filings, most recently posting -$29.7 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$29.7 million, up 47.45% year-over-year; the trailing twelve-month figure through Mar 2026 was -$114.6 million (up 16.16% YoY), and the FY2025 annual result was -$141.4 million, down 13.42% from the prior year.
• Free Cash Flow came in at -$29.7 million for Q1 2026 at ADC Therapeutics, up from -$31.4 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$15.8 million in Q1 2023 to a low of -$56.6 million in Q1 2025.
• The 4-year median for Free Cash Flow is -$29.7 million (2026), against an average of -$31.9 million.
• Across the five-year window, Free Cash Flow sank 182.39% in 2024 and soared 47.45% in 2026, its largest moves.
• ADC Therapeutics' Free Cash Flow stood at -$28.8 million in 2023, then increased by 21.27% to -$22.7 million in 2024, then plunged by 38.38% to -$31.4 million in 2025, then gained by 5.24% to -$29.7 million in 2026.
• The last three Free Cash Flow figures came in at -$29.7 million (Q1 2026), -$31.4 million (Q4 2025), and -$29.4 million (Q3 2025), per Business Quant data.